Author details

Full Name

Elke Pfaff

Affiliation

ORCID

Career Start Year

2010

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37364231	Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM.	JCO Precis Oncol	2023
37776353	Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristics.	Acta Neuropathol	2023
36966138	Genomic characterization of DICER1-associated neoplasms uncovers molecular classes.	Nat Commun	2023
34116162	Precision medicine in pediatric solid cancers.	Semin Cancer Biol	2022
34994601	<i>NTRK</i> Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets.	JCO Precis Oncol	2021
33627664	Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome.	Nat Commun	2021
34545083	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B.	Nat Commun	2021
34373263	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets.	Cancer Discov	2021
32503469	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies.	BMC Cancer	2020
31768671	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations.	Acta Neuropathol	2020
31022591	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.	Eur J Cancer	2019
30277538	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.	Neuro Oncol	2019
29746225	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries.	J Clin Oncol	2018
30030436	Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma.	Nat Commun	2018
29489754	The landscape of genomic alterations across childhood cancers.	Nature	2018
29165638	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.	Neuro Oncol	2018
27479119	Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.	Eur J Cancer	2016
26919435	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.	Cell	2016
24651015	Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.	Cancer Cell	2014
25539912	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.	Acta Neuropathol Commun	2014
23835706	Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.	J Clin Oncol	2013
23817572	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.	Nat Genet	2013
22265402	Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations.	Cell	2012
22286061	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.	Nature	2012
22832583	Dissecting the genomic complexity underlying medulloblastoma.	Nature	2012
23079654	Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.	Cancer Cell	2012
22160402	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.	Acta Neuropathol	2012
21060032	TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.	J Clin Oncol	2010